NEUROKIN strengthens its Board of Directors and Scientific Committee

01-Nov-2010 - France

NEUROKIN announced the appointment of Mr. Bernard Reculeau as a new member of the Board of Directors, and the arrival of Mr. Jesús Benavides within the company’s Scientific Committee.

Bernard has over 25 years of experience in leadership positions in the pharmaceutical industry. At Rhone Poulenc since 1984, he served as General Manager of Pharmuka (launch of Lovenox in France), Senior Vice President Worldwide Industrial Operations, Senior Vice President France and Benelux and finally, Senior Vice President and General manager of Rhone-Poulenc Rorer International. Bernard continued his career at Aventis, where he served as Senior Vice President of pharmaceutical operations until 2005. Bernard also has a good knowledge of biotechnology companies, since he led CISBIO from 2006 to late 2009 and is still, since 2005, a member of the Board of Directors of the Canadian company Theratechnologies.

Bernard graduated from the Institut d’Etudes Politiques de Paris (1974) and the Ecole Nationale d’Administration (1977).

Jesus’ scientific expertise is based on nearly 30 years of experience in R&D within the pharmaceutical industry. He headed until 2000, the department of neurobiology of Sanofi-Synthelabo Research Unit. Between 2000 and 2010 he held various management positions in R&D at Aventis and Sanofi-Aventis. He was Vice President and Head of the Neurodegenerative Diseases Research of Aventis before becoming Vice President and Global Head of Research in Neurology. Nowadays, Jesus also teaches translational neurology in France and Spain; he is a Consultant in pharmaceutical R&D for Pharmaceutical companies and Biotech companies in the field of central nervous system.

Jesús holds a Ph.D. in Biochemistry (Molecular Biology center - University of Madrid).

https://www.bionity.com/en/news/125290/neurokin-strengthens-its-board-of-directors-and-scientific-committee.html